On September 28, 2020 Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, reported listing of its ordinary shares on the Main Board of The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange") under the stock code "9688" and the closing of its previously-announced Hong Kong secondary listing (the "Hong Kong Secondary Listing") of 10,564,050 new ordinary shares (the "Offer Shares" or "Shares") which comprises an international offering (the "International Offering") and a Hong Kong public offering (the "Hong Kong Public Offering," and together with the International Offering, the "Offering") (Press release, Zai Laboratory, SEP 28, 2020, View Source [SID1234567666]). The final offer price for both the International Offering and the Hong Kong Public Offering (the "Offer Price") has been set at HK$562.00 per Share. Based on the ratio of one (1) ordinary shares per Nasdaq-listed American depositary share ("ADS"), the Offer Price translates to approximately US$72.52 per ADS. The Company had also granted the international underwriters an over-allotment option, exercisable from September 22, 2020 until 30 days thereafter, to require the Company to issue up to an additional 1,584,600 new Shares at the Offer Price.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The gross proceeds to Zai Lab from this Offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately HK$5.94 billion.

J.P. Morgan Securities (Far East) Limited (or its affiliates, as the case may be), Goldman Sachs (Asia) L.L.C. and Citigroup Global Markets Asia Limited (or its affiliate, as the case may be) are the joint sponsors, joint global coordinators, joint bookrunners and joint lead managers for the proposed Hong Kong Secondary Listing.

The International Offering was made only by means of a prospectus supplement dated September 22, 2020 and the accompanying prospectus included in an automatic shelf registration statement on Form F-3ASR filed with the U.S. Securities and Exchange Commission (the "SEC") on March 29, 2019 and was subsequently amended and became automatically effective upon filing with the SEC on January 21, 2020. The registration statement on Form F-3ASR and the prospectus supplement dated September 22, 2020 are available at the SEC website at: View Source Copies of the prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from: (i) J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-866-803-9204 or by email at [email protected], (ii) Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282 or by telephone at 1-866-471-2526, or (iii) Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-800-831-9146 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer or an invitation to buy any securities, nor shall there be any offer or sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. This press release does not constitute a prospectus (including as defined under the laws of Hong Kong) and potential investors should read the prospectus of the Company for detailed information about the Company and the proposed offering, before deciding whether or not to invest in the Company. This press release has not been reviewed or approved by the Hong Kong Stock Exchange or the Securities and Futures Commission of Hong Kong.

The price of the Shares of the Company may be stabilized in accordance with the Securities and Futures (Price Stabilization) Rules. The details of the intended stabilization and how it will be regulated under the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong) have been contained in the prospectus of the Company dated September 17, 2020.

On September 28, 2020 Illumina, Inc. (NASDAQ:ILMN) reported that it will issue results for the third quarter 2020 following the close of market on Thursday, October 29, 2020 (Press release, Illumina, SEP 28, 2020, View Source [SID1234567688]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, President and Chief Executive Officer, and Sam Samad, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Conference Call Details

The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Thursday, October 29, 2020. Interested parties may access the live teleconference through the Investor Info section of Illumina’s website under the "company" tab at www.illumina.com. Alternatively, individuals can access the call by dialing 1 (866) 211-4597 or 1 (647) 689-6853 outside North America, both with Conference ID 9488740. To ensure timely connection, please dial in at least ten minutes before the scheduled start of the call.

A replay of the conference call will be posted on Illumina’s website after the event and will be available for at least 30 days following.

On September 28, 2020 Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that an Independent Monitoring Committee (IDMC) determined that the randomized, double-blind, placebo-controlled, international multi-center Phase III study JUPITER-02 at the interim analysis had met its pre-specified primary endpoint (Press release, Shanghai Junshi Bioscience, SEP 29, 2020, View Source [SID1234567842]). The results of the study showed that Toripalimab in combination with Gemcitabine/Cisplatin as a first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) significantly extended the progression-free survival than the current standard treatment of Gemcitabine/Cisplatin. The Company will submit biologic license application (BLA) to the National Medical Products Administration (the "NMPA") and regulatory authorities in other relevant countries in the near future.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

About NPC
Nasopharyngeal carcinoma (NPC), a subtype of head and neck cancer, is a malignant tumor that occurs in the nasopharynx. According to statistics from the World Health Organization, NPC is widely distributed in Southeast Asia and the incidence in the region accounts for approximately 84.6% of the new cases worldwide. NPC is prone to distant metastasis at diagnosis, while early stage patients tend to relapse after radiation or radio-chemotherapy. Platinum-based therapy is currently standard care for recurrent or metastatic NPC. In addition, there is no standard treatment after failure of the first-line systemic chemotherapy. The 5-year overall survival rate of patients with advanced disease is less than 10%.

ABOUT JUPITER-02 STUDY
The JUPITER-02 Study (NCT03581786) is a randomized, double-blind, placebo-controlled, international multi-center Phase III clinical study to compare the efficacy and safety of Toripalimab versus placebo in combination with Gemcitabine/Cisplatin, as a first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma. Professor Xu Ruihua from Sun Yat-sen University Cancer Centre is the leading principal investigator. The JUPITER-02 Study enrolled a total of 289 patients. The primary endpoint of the study is progression-free survival (PFS), and the secondary endpoints include overall survival (OS), objective response rate (ORR), duration of response (DOR), disease control rate (DCR) and safety.

At the interim analysis, the Independent Data Monitoring Committee (IDMC) determined that the global study met its primary endpoint of progression free survival (PFS). Compared with the placebo control, Toripalimab in combination with Gemcitabine/Cisplatin significantly prolonged the PFS as a first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma.

About Toripalimab
Toripalimab is a PD-1 monoclonal antibody developed by Junshi Biosciences. Toripalimab received its first approval for 2nd line treatment of metastatic melanoma on December 17, 2018 in China and was commercially launched in February 2019. More than 30 clinical studies covering more than ten cancer indications have been conducted in China, the United States and other countries.

In April 2020, the supplemental New Drug Application ("NDA") of Toripalimab for the treatment of recurrent/metastatic nasopharyngeal carcinoma after failure of at least two prior systemic treatments has been accepted by the NMPA. This supplemental NDA is the world’s first NDA of PD-1 blockade therapy for the treatment of nasopharyngeal carcinoma. In May 2020, the supplemental NDA of Toripalimab for the treatment of locally advanced or metastatic urothelial carcinoma after systemic treatment has been accepted by the NMPA. Both supplemental NDAs received priority review status by the NMPA in July 2020.

In March 2020, Toripalimab in combination with axitinib for the treatment of mucosal melanoma was granted the orphan-drug designation by the US FDA. In May and September 2020, Toripalimab also received the orphan-drug designation by the FDA for the treatment of nasopharyngeal carcinoma and soft tissue sarcoma. In September 2020, Toripalimab for the treatment of nasopharyngeal carcinoma was granted the Breakthrough Therapy designation by the FDA.

On September 28, 2020 NeuBase Therapeutics, Inc. (NASDAQ: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, reported that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the Chardan Virtual 4TH Annual Genetic Medicines Conference being held on October 5 – 6 (Press release, NeuBase Therapeutics, SEP 28, 2020, View Source [SID1234567667]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conferences Details:
Event: Chardan Virtual 4TH Annual Genetic Medicines Conference
Format: Fireside Chat
Date: Monday, October 5TH
Time: 11:30 a.m. ET
Location: Webcast Link – or at the company’s website (click here)

On September 28, 2020 Accent Therapeutics reported that it has been named by Fierce Biotech as one of 2020’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry (Press release, Accent Therapeutics, SEP 28, 2020, View Source [SID1234567691]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Accent is a leader in the development of small molecule therapies that selectively inhibit RNA-modifying proteins (RMPs) that drive cancer. By targeting RMPs, the company is taking a novel approach to unlocking the potential of RNA biology by targeting enzymes responsible for post-transcriptional chemical modifications of RNA. Accent is developing a rich pipeline of oncology-focused therapies in a new class of medicines that target RMPs.

"We are honored to be recognized by Fierce Biotech as a leader in the biotech landscape, pursuing novel RMP-targeted therapies to bring new and potentially life-changing medicines to patients," said Shakti Narayan, Chief Executive Officer, Accent Therapeutics. "This recognition is a tribute to our team’s fierce commitment to giving patients living with cancer greater hope, fewer burdens and the promise of a life beyond disease."

The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. This is Fierce Biotech’s 18th annual Fierce 15 selection.

"The 2020 Fierce 15 comes at a time when the world is focused on a pandemic, but even as coronavirus remains a threat, patients with cancer, rare diseases and other disorders still need treatment," Fierce Biotech Senior Editor Ben Adams said. "This year, we’ve chosen from a diverse range of those fighting COVID, as well as those fighting longer term plagues against our biology," Adams said.

An internationally recognized daily report reaching a network of over 285,000 biotech and pharma industry professionals, Fierce Biotech provides subscribers with an authoritative analysis of the day’s top stories. Every year Fierce Biotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.